2025-12-28 - Analysis Report
Okay, here's a report on Tempus AI Inc. (TEM) based on the provided data:

**1. Return Rate Analysis:**

*   **TEM Overview:** Tempus AI Inc. is [Based on general knowledge, Tempus AI Inc. is a technology company focused on precision medicine through data analytics, using AI to personalize healthcare].
*   **TEM Cumulative Return:** 11.92%
*   **S&P 500 (VOO) Cumulative Return:** 32.43%
*   **Divergence:** -15.0 (Relative Divergence: 22.3)

**Analysis:** TEM has significantly underperformed the S&P 500. The divergence of -15.0 indicates a substantial difference in cumulative returns. The relative divergence of 22.3 suggests the current divergence is near the lower end of its historical range.

**Alpha, Beta Analysis:**

| Year       | CAGR | MDD  | Alpha | Beta | Cap(B) |
|------------|------|------|-------|------|-------|
| 2023-2025  | 12.0% | 76.7% | -20.0% | 0.3 | 11.2 |

**Analysis:**

*   **CAGR (Compound Annual Growth Rate):** A 12.0% CAGR indicates moderate annual growth over the period.
*   **MDD (Maximum Drawdown):** A high MDD of 76.7% suggests significant volatility and potential for large losses.
*   **Alpha:** A negative Alpha of -20.0% implies underperformance relative to its benchmark (likely the S&P 500) after accounting for risk.
*   **Beta:** A Beta of 0.3 indicates the stock is less volatile than the market.
*   **Cap(B):** A market cap of 11.2 Billion is a mid-cap stock.

**2. Recent Stock Price Fluctuations:**

*   **Current Close:** 62.70
*   **Last Market Data:**
    *   Price: 62.70
    *   Previous Close: 64.26
    *   Change: -2.43
*   **Moving Averages:**
    *   5-day SMA: 64.41
    *   20-day SMA: 70.72
    *   60-day SMA: 78.98

**Analysis:** The stock is currently trading below its 5-day, 20-day, and 60-day Simple Moving Averages (SMAs), suggesting a short-term downtrend.  The recent price decline is also reflected in the negative change from the previous close.

**3. Indicator Analysis:**

*   **Market Risk Indicator (MRI):** 1.0 (High Investment Recommended)
*   **RSI:** 18.47 (Oversold)
*   **PPO:** -0.95
*   **Hybrid Signal:** cash_0%_Buy 100% of cash (14 shares - Very Safe - MRI:0.90) Monthly invest 5.0% of total investment ($1,000.00) (Cash Ratio: 0% on 2025-12-01)
*   **Recent Divergence Change:** -9.7 (Negative - Short-term Decline)
*   **Expected Return:** NaN

**Analysis:**

*   **MRI:**  Although the MRI indicates high investment recommendation, it contradicts with other analysis.
*   **RSI:** The RSI is extremely low, indicating the stock is heavily oversold and may be due for a rebound.
*   **PPO:** The negative PPO supports the downtrend.
*   **Hybrid Signal:**  The hybrid signal suggests a "Buy" recommendation based on the model parameters, which include MRI, suggesting it is a 'Very Safe' investment at its current levels.
*   **Recent Divergence Change:** Reinforces the recent decline and the underperformance compared to the S&P 500.
*   **Expected Return:** The NaN value for expected return is a significant concern, suggesting that either the calculation could not be performed, or the input data does not allow a calculation.

**4. Recent News & Significant Events:**

*   **Negative News:**
    *   Stock fell 3% this week.
    *   Insider Selling by the CEO.
*   **Positive News:**
    *   Stock is up 87% in 2025 (year-to-date at the time of the article).
    *   Advancing toward regulatory pricing catch-up.
*   **Mixed/Neutral News:**
    *   Buy, Hold, or Sell analysis.
    *   Omeros stock pop due to approval (unclear if this directly impacts TEM).

**Analysis:** The news presents a mixed picture.  While the year-to-date performance sounds impressive, recent performance is negative. Insider selling is generally viewed negatively. The article about regulatory pricing catch-up is a potentially positive development.

**4-2. Analyst Opinions:**

*   **Consensus:** Buy (Mean: 2.14)
*   **Opinions:** 12
*   **Target Price:** Average: 88.92, High: 105.00, Low: 80.00

**Analysis:** Despite the recent underperformance, analysts maintain a positive outlook with a "Buy" consensus and a significant upside potential based on target prices.

**5. Comprehensive Analysis:**

Tempus AI (TEM) is currently facing a challenging situation. While analysts maintain a "Buy" rating and see significant upside potential, the stock is underperforming the S&P 500, experiencing a short-term downtrend, and showing high volatility. The RSI indicates that the stock may be oversold and the hybrid signal suggests a buy. Recent news is mixed, with some positive developments offset by negative headlines, especially insider selling and recent price declines. The very high MRI is unusual and inconsistent with other factors in the analysis.

**Conclusion:**

The investment decision depends on your risk tolerance and investment horizon. The positive analyst ratings and potential regulatory pricing catch-up might attract investors willing to weather the volatility. However, the recent underperformance, negative divergence change, and insider selling are reasons for caution. A thorough investigation into TEM's financials, business strategy, and competitive landscape is warranted before making an investment decision.


**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.